In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer. They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options…

In this episode, Kristen Lamoreau, OD, delves into the critical role eye care professionals play in managing ocular adverse events for patients undergoing treatment with ELAHERE, the first and only antibody-drug conjugate targeting folate receptor alpha (FRα). As a groundbreaking treatment for certain types of resistant ovarian cancer, ELAHERE is a…

Welcome to episode three of three. In this episode, Dr. Alex Spira and Dr. Josh Zabari, both experts in thoracic oncology, delve into the common side effects experienced by patients undergoing treatment for locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). They discuss the importance of early identification and management of …

Welcome to episode two of three where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). Explore the unmet needs in first-line therapy, the variety of resistance mechani…

Welcome to episode one of three, where we dive deep into the challenges and advancements in managing locally Advanced or Metastatic EGFR+ Non-Small-Cell Lung Cancer (NSCLC). This educational opportunity is brought to you by Johnson & Johnson. Join Dr. Mark Socinski, Executive Medical Director of the Advent Health Cancer Institute, and Dr. Dave Wate…